Global IPV Vaccines Market, by Vaccine Brand (POLIOVAC (PFS/SD), SHANIPV, POLIORIX, IPOL/IMOVAX, And POLYMILEX), by Distribution Channel (Private and Public), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 160 in 2021 and is expected to exhibit a CAGR of 8.5% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Key players operating in the market are focusing on launches and agreements from regulatory authorities and this is expected to drive the market growth over the forecast period.
For instance, in May 2018, according to WHO, on 2 January 2018, Turkmenistan introduced IPV, the Republic of Moldova on 2 April 2018, Uzbekistan on 24 April 2018, and Kyrgyzstan on 2 May 2018, are the four countries in Europe, who introduced the inactivated poliovirus vaccine to their Routine Immunization Programme.
Global IPV Vaccines Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 260 million cases and 5.2 million deaths due to Coronavirus (COVID-19) were reported up till November 29, 2021, across the globe.
As per stated in research article, About 31% of utilization of vaccination services at the national level decreased. Mainly between February and April 2020, the immunization services provision diminished by 46.9% in private sector. The vaccination campaigns were suspended in Pakistan in April due to COVID-19 pandemic and more than 40 million children were not able to take the polio vaccine. Pakistan and India are the two countries who have large number of missed childhood vaccination. Pakistan and India are the two countries who have large number of missed childhood vaccination.
Within the same time, the pandemic increased the public awareness on public health and benefits of vaccination one can have.
Browse 40 Market Data Tables and 35 Figures spread through 220 Pages and in-depth TOC on “Global IPV Vaccines Market”- Global Forecast to 2028, by Vaccine Brand (POLIOVAC (PFS/SD), SHANIPV, POLIORIX, IPOL/IMOVAX, and POLYMILEX), by Distribution Channel (Private and Public), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global IPV Vaccines Market, click the link below:
Key players operating in the market are focusing on adoption of inorganic growth strategies such as mergers, approvals, collaborations, and acquisitions, in order to strengthen their position in the global market. For instance, in June 2018, AJ Vaccines, a global pharmaceutical company, received marketing approval for the adjuvant Inactivated Polio Vaccine (IPV) vaccine, Picovax, from the Danish Medicines Agency (DMA). Picovax provides active immunization against poliomyelitis as primary vaccination in infants from the age of 6 weeks and for revaccination of infants, children, adolescents, and adults.
Key Takeaways of the Global IPV Vaccines Market